For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Guidelines : Overactive bladder (adults)
Guidelines : Overactive bladder (adults)
Additional Documents
Other Drugs
- Darifenacin hydrobromide
- Flavoxate hydrochloride
- Oxybutynin
- Propiverine hydrochloride
- Solifenacin
- Mirabegron
- Fesoterodine fumarate
- Trospium chloride
- Tolterodine
- Imipramine hydrochloride
Committee Recommendations
The following resources have been agreed by the APC to support patients in trialling a treatment break of their overactive bladder medicines:
- Leaflet for trial of stopping anticholinergics
- Leaflet for trial of stopping mirabegron
These resources can be found in the documents section.
The Surrey Heartlands APC recommend the management of overactive bladder and LUTS in line with CKS:
LUTS in men, https://cks.nice.org.uk/topics/luts-in-men/management/overactive-bladder/
Incontinence in women, Incontinence - urinary, in women | Health topics A to Z | CKS | NICE
Cost-effective treatment choices have been agreed locally as follows
- Solifenacin 1st line
Swallowing difficulties:
- Solifenacin Oral Suspension 1mg/ml Sugar Free
- Oxybutynin Transdermal Patches (if oral route not suitable)
Contraindication or solifenacin not suitable - see Selection Tool for other treatment options
Stopping
Recommend that treatment of overactive bladder should be reviewed every 6-12 months with consideration of, or a trial of, discontinuation.
Switching
Recommend the switching from other anticholinergics prescribed for overactive bladder to one of the approved treatments which provide a very cost-effective range of products if clinically appropriate and following a discussion between the patient and the responsible
prescriber.